Thus, the most prominent findings of the present study that the anti-ENO1 antibody, MET combined with DDP/CTX could simultaneously target both CSCs subpopulations and produce stronger additive inhibition to overcome drug resistance, which highlighted the validity of antibody-based drug combination therapy against cancer resistance and the potential as precursor platform of ADC screening. Here, ENO1 is linked to cancer.